Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Pipeline Developments
SLNO logo

Soleno Therapeutics Reaches Profitability with $190.4 Million in First-Year Product Revenue

SLNO10-KFiling Date: 2/25/2026
Soleno Therapeutics, Inc.
Description

What this story covers

Soleno Therapeutics achieved profitability in 2025 after VYKAT XR's FDA approval for Prader-Willi Syndrome. The company generated $190.4 million in revenue, secured a strong cash position, and is now focused on European and international expansion.

Story snapshot

CompanySoleno Therapeutics, Inc.
TickerSLNO
VariantStandard detailed
Duration12:02
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001193125-26-071808
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in